- Tables of Contents (Vol. 55, No. 1~4, 2023)
-
- KMID: 2547811
- Cancer Res Treat.
- 2023 Oct;55(4):1369-1380.
-
- CITED
-
- Close
- SHARE
-
- Close
- Acknowledgment of Reviewers (2023)
-
- KMID: 2547812
- Cancer Res Treat.
- 2023 Oct;55(4):1381-1384.
-
- CITED
-
- Close
- SHARE
-
- Close
- Health-Seeking Behavior Returning to Normalcy Overcoming COVID-19 Threat in Breast Cancer
-
Lee EG, Han Y, Lee DE, Moon HG, Koh HW, Kim EK, Jung SY
- KMID: 2547796
- Cancer Res Treat.
- 2023 Oct;55(4):1222-1230.
- doi: 10.4143/crt.2023.364
Purpose The coronavirus disease 2019 (COVID-19) outbreak has significantly impacted the diagnosis and treatment of breast cancer. Our study investigated the change in diagnosis and treatment of breast cancer with... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent Developments in the Therapeutic Landscape of Advanced or Metastatic Hormone Receptor–Positive Breast Cancer
-
Lee EY, Lee DW, Lee KH, Im SA
- KMID: 2547781
- Cancer Res Treat.
- 2023 Oct;55(4):1065-1076.
- doi: 10.4143/crt.2023.846
Hormone receptor–positive (HR+) disease is the most frequently diagnosed subtype of breast cancer. Among tumor subtypes, natural course of HR+ breast cancer is indolent with favorable prognosis compared to other... -
- CITED
-
- Close
- SHARE
-
- Close
- Barriers in Oligometastasis Care in Korea: Radiation Oncologists’ Perspectives
-
Chie EK, Rim CH, Cho WK, Ahn YC
- KMID: 2547780
- Cancer Res Treat.
- 2023 Oct;55(4):1063-1064.
- doi: 10.4143/crt.2023.780
-
- CITED
-
- Close
- SHARE
-
- Close
- Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients
-
Choi W, Kim YH, Woo SM, Yu Y, Lee MR, Lee WJ, Chun JW, Sim SH, Chae H, Shim H, Lee KS, Kong SY
- KMID: 2547782
- Cancer Res Treat.
- 2023 Oct;55(4):1077-1086.
- doi: 10.4143/crt.2022.1630
Purpose Patient-derived tumor cells can be a powerful resource for studying pathophysiological mechanisms and developing robust strategies for precision medicine. However, establishing organoids from patient-derived cells is challenging because of... -
- CITED
-
- Close
- SHARE
-
- Close
- Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma
-
Ryu KH, Park S, Chun JW, Cho E, Choi J, Lee DE, Shim H, Kim YH, Han SS, Park SJ, Woo SM, Kong SY
- KMID: 2547804
- Cancer Res Treat.
- 2023 Oct;55(4):1303-1312.
- doi: 10.4143/crt.2023.291
Purpose The genetic attribution for pancreatic ductal adenocarcinoma (PDAC) has been reported as 5%-10%. However, the incidence of germline pathogenic variants (PVs) in Korean PDAC patients has not been thoroughly... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety and Tolerability of Weekly Genexol-PM, a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel, with Carboplatin in Gynecologic Cancer: A Phase I Study
-
Nam SH, Lee SW, Lee YJ, Kim YM
- KMID: 2547808
- Cancer Res Treat.
- 2023 Oct;55(4):1346-1354.
- doi: 10.4143/crt.2022.1436
Purpose This phase I study was conducted to determine the maximum tolerated dose and the recommended phase II dose of weekly administered Genexol-PM combined with carboplatin in patients with gynecologic... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Outcome of Stereotactic Body Radiotherapy in Patients with Early-Stage Lung Cancer with Ground-Glass Opacity Predominant Lesions: A Single Institution Experience
-
Jang JY, Kim SS, Song SY, Shin YS, Lee SW, Ji W, Choi CM, Choi EK
- KMID: 2547792
- Cancer Res Treat.
- 2023 Oct;55(4):1181-1189.
- doi: 10.4143/crt.2022.1656
Purpose The detection rate of early-stage lung cancer with ground-glass opacity (GGO) has increased, and stereotactic body radiotherapy (SBRT) has been suggested as an alternative to surgery in inoperable patients. However,... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy
-
Ma Y, Zhu M, Zhang J, Lv M, Chen X, Liu Z
- KMID: 2547795
- Cancer Res Treat.
- 2023 Oct;55(4):1210-1221.
- doi: 10.4143/crt.2022.1633
Purpose Patients with human epidermal growth factor receptor 2 (HER2)–low advanced breast cancer can benefit from trastuzumab deruxtecan. Given the unclear prognostic characteristics of HER2-low breast cancer, we investigated the... -
- CITED
-
- Close
- SHARE
-
- Close
- Outcomes of Salvage Therapy for Oropharyngeal Cancer Recurrence Following Upfront Radiation Therapy and Prognostic Factors
-
Choi N, Kim HJ, Yi H, Kim H, Kim TH, Jeong HS, Son YI, Baek CH, Oh D, Ahn YC, Chung MK
- KMID: 2547787
- Cancer Res Treat.
- 2023 Oct;55(4):1123-1133.
- doi: 10.4143/crt.2022.1046
Purpose This study aimed to investigate the oncologic outcomes and prognostic factors of salvage treatments in patients with recurrent oropharyngeal squamous cell carcinoma (OPSCC) after radiotherapy (RT)-based treatment. Materials and Methods... -
- CITED
-
- Close
- SHARE
-
- Close
- Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
-
Kim M, Kim S, Yim J, Keam B, Kim TM, Jeon YK, Kim DW, Heo DS
- KMID: 2547788
- Cancer Res Treat.
- 2023 Oct;55(4):1134-1143.
- doi: 10.4143/crt.2023.311
Purpose In patients with epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer (NSCLC), EGFR tyrosine kinase inhibitors (TKIs) improve response rate and survival. However, most patients eventually develop resistance.... -
- CITED
-
- Close
- SHARE
-
- Close
- Sublobar Resection versus Stereotactic Body Radiation Therapy for Clinical Stage I Non–Small Cell Lung Cancer: A Study Using Data from the Korean Nationwide Lung Cancer Registry
-
Yun J, Cho JH, Hong TH, Yang K, Ahn YC, Kim HK, Korean Association for Lung Cancer, Korea Central Cancer Registry
- KMID: 2547791
- Cancer Res Treat.
- 2023 Oct;55(4):1171-1180.
- doi: 10.4143/crt.2022.1581
Purpose Stereotactic body radiotherapy (SBRT) had been increasingly recognized as a favorable alternative to surgical resection in patients with high risk for surgery. This study compared survival outcomes between sublobar... -
- CITED
-
- Close
- SHARE
-
- Close
- Specific Mutations in APC, with Prognostic Implications in Metastatic Colorectal Cancer
-
Peng H, Ying J, Zang J, Lu H, Zhao X, Yang P, Wang X, Li J, Gong Z, Zhang D, Wang Z
- KMID: 2547801
- Cancer Res Treat.
- 2023 Oct;55(4):1270-1280.
- doi: 10.4143/crt.2023.415
Purpose Loss-of-function mutations in the adenomatous polyposis coli (APC) gene are common in metastatic colorectal cancer (mCRC). However, the characteristic of APC specific mutations in mCRC is poorly understood. Here,... -
- CITED
-
- Close
- SHARE
-
- Close
- Should We Perform Repeated Re-biopsy for the Detection of T790M Mutation?
-
Kim S, Kim SH, Kim J, Kim MH, Lee MK, Eom JS
- KMID: 2547793
- Cancer Res Treat.
- 2023 Oct;55(4):1190-1197.
- doi: 10.4143/crt.2023.320
Purpose Epidermal growth factor receptor (EGFR) T790M mutations have been detected in the second or third rebiopsy, even if the T790M mutation was not identified in the first rebiopsy. This... -
- CITED
-
- Close
- SHARE
-
- Close
- Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy
-
Ji P, Lu Q, Chen X, Chen Y, Peng X, Chen Z, Lin C, Lin S, Zong J
- KMID: 2547786
- Cancer Res Treat.
- 2023 Oct;55(4):1113-1122.
- doi: 10.4143/crt.2022.1651
Purpose This retrospective study aimed to re-evaluate the effect of concurrent chemotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC) in the era of intensity-modulated radiotherapy (IMRT). Materials and Methods A... -
- CITED
-
- Close
- SHARE
-
- Close
- Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
-
Jeon Y, Jung HA, Park S, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH
- KMID: 2547789
- Cancer Res Treat.
- 2023 Oct;55(4):1144-1151.
- doi: 10.4143/crt.2023.403
Purpose Rearranged during transfection (RET) gene rearrangement is a well-known driver event in non–small cell lung cancer (NSCLC). Pralsetinib is a selective inhibitor of RET kinase and has shown efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor–Positive Metastatic Breast Cancer
-
Kim SG, Kim MH, Park S, Kim GM, Kim JH, Kim JY, Park HS, Park S, Park BW, Kim SI, Ji JH, Jeong J, Shin K, Lee J, Kim HD, Jung KH, Sohn J
- KMID: 2547794
- Cancer Res Treat.
- 2023 Oct;55(4):1198-1209.
- doi: 10.4143/crt.2022.1543
Purpose Frequent neutropenia hinders uninterrupted palbociclib treatment in patients with hormone receptor (HR)–positive breast cancer. We compared the efficacy outcomes in multicenter cohorts of patients with metastatic breast cancer (mBC)... -
- CITED
-
- Close
- SHARE
-
- Close
- Development and Validation of Models to Predict Lymph Node Metastasis in Early Gastric Cancer Using Logistic Regression and Gradient Boosting Machine Methods
-
Lee HD, Nam KH, Shin CM, Lee HS, Chang YH, Yoon H, Park YS, Kim N, Lee DH, Ahn SH, Kim HH
- KMID: 2547798
- Cancer Res Treat.
- 2023 Oct;55(4):1240-1249.
- doi: 10.4143/crt.2022.1330
Purpose To identify important features of lymph node metastasis (LNM) and develop a prediction model for early gastric cancer (EGC) using a gradient boosting machine (GBM) method. Materials and Methods The clinicopathologic... -
- CITED
-
- Close
- SHARE
-
- Close
- Differential Perspectives by Specialty on Oligometastatic Colorectal Cancer: A Korean Oligometastasis Working Group’s Comparative Survey Study
-
Cho WK, Yoo GS, Rim CH, Jeong JU, Chie EK, Ahn YC, Cho HM, Um JW, Suh YG, Chang AR, Lee JH, On behalf of the Oligometastasis Working Group, Korean Cancer Association
- KMID: 2547802
- Cancer Res Treat.
- 2023 Oct;55(4):1281-1290.
- doi: 10.4143/crt.2023.479
Purpose Despite numerous studies on the optimal treatments for oligometastatic disease (OMD), there is no established interdisciplinary consensus on its diagnosis or classification. This survey-based study aimed to analyze the... -
- CITED
-
- Close
- SHARE
-
- Close
